Navigation Links
Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies
Date:3/17/2009

Complimentary Continuing Education Lecture for Healthcare Professionals

VOORHEES, N.J., March 17 /PRNewswire/ -- Hereditary angioedema (HAE) is estimated to afflict 10,000 people in the United States each year. Patients with HAE suffer from recurrent attacks of intense localized edema involving the skin, airway, and visceral organs. Left untreated, most patients will suffer at least one acute attack per month. Chronic therapy with attenuated androgens or plasmin inhibitors has been the mainstay of therapy. However, many new therapies are on the horizon, offering hope to thousands who suffer from this debilitating disease.

To address the need for current education on HAE, Robert Michael Educational Institute LLC (RMEI) and Postgraduate Institute for Medicine (PIM) are jointly sponsoring complimentary continuing education lectures at institutions across the United States. This continuing education activity, titled Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies, is supported by an educational grant from ViroPharma Incorporated and is accredited for physicians, nurses, and pharmacists.

The faculty for these lectures comprises experts in immunology and HAE from leading medical institutions. The chairperson is Bruce L. Zuraw, MD, Professor of Medicine and Chief of the Section of Allergy and Immunology at the University of California School of Medicine in San Diego, CA.

Healthcare professionals can visit www.RMEI.com, e-mail HAELectures@RMEI.com, or phone toll-free (877) 547-5642 to schedule a lecture at their institution.

"Quality continuing education is vital to developing and increasing knowledge and skills and enhancing patient care," says Robert Michael Educational Institute LLC President and CEO, Robert M. Colleluori.

RMEI is a medical education company that specializes in independent, accredited and non-accredited education. The goal of all accredited RMEI educational offerings is to promote a spirit of lifelong learning and continuous professional development. RMEI works closely with medical experts to design activities that improve diagnosis and treatment. These activities include national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.

For other educational opportunities, please visit www.RMEI.com.


'/>"/>
SOURCE Robert Michael Educational Institute LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
2. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
3. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
4. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
5. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
6. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
7. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
8. High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
9. Nations Foremost Health Care Leaders Kick Off Summit Focused on Zero-Tolerance Approach to Hospital-Acquired Infections
10. Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A
11. New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released a ... books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture of ... have tossed it off as mere rubbish, but Yisrayl Hawkins says that is because ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... Maryland (PRWEB) , ... October 12, 2017 , ... ... magnetic drug delivery system that we intend to develop to enable prevention of ... can lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & Wellness ... Moonlight to raise money for the American Heart Association Heart Walk. Teams of up ... work together to keep their treadmills moving for 5 hours. Treadmills will start at ...
Breaking Medicine News(10 mins):